H1

The COG: CRO Summit is next week! Our own Ryan B. will speak about “Driving Diversity, Equity & Inclusion in Clinical Trials: A Data-Driven Approach.” We hope you’ll join us to learn new strategies for selecting trials sites to improve diversity and health equity. And we invite you to visit booth 20 to find out how H1's data and analytics support successful and equitable clinical trials. See you there! PBC Group - Organisers of the COG Series #crosummit #crosummit2024 #healthequity #clinicaltrialdiversity #healthcaretechnology

GSK is working to bring relief to thousands of liver disease patients who suffer from relentless itching. GSK projects that 510,000 people will have been diagnosed with primary biliary cholangitis (PBC) by 2030 and nearly half of those patients will experience relentless itching. GSK’s phase 3 trial of their treatment linerixibat hit its primary endpoint, significantly reducing the monthly itch score after 24 weeks compared to placebo. Linerixibat has the potential to be the first global therapy indicated to treat itch in PBC. https://hubs.la/Q02YJW200 #gsk #liverdisease #linerixibat #primarybiliarycholangitis #pbc #cholestaticpruritus #relentlessitching

The most successful #MSL strategy is one that aligns #HCP insights to internal business goals. Understanding HCP backgrounds, activities and priorities makes it easier to build a solid territory business plan. Katie Shin incorporated H1’s HCP data into her territory planning to create an individualized strategy for her team at Sumitomo Pharma America, Inc. Watch here: https://hubs.la/Q02YVlnZ0 You can learn more about HCP Universe here: https://hubs.la/Q02YVmz50 #sumitomo #smpa #territorymapping #mslterritoryplanning #hcpdata #hcpinsights

Diversity in clinical trials goes beyond regulatory requirements—it’s a cornerstone of ethical research and scientific integrity. So how can clinical research teams use data-driven approaches to foster diversity in research? Ryan B., H1’s Regional VP of Sales, shares about the critical need for diverse populations in clinical studies in this Xtalks Spotlight with?Vera Kovacevic. Ryan explores how clinical research teams can use data-driven approaches to foster diversity in research. Watch now: https://lnkd.in/eMsKtWgf #clinicaltrialdiversity #healthequity #patientdiversity #equitableresearch #xtalks #patientrepresentation

Will you be attending the COG: CRO Summit? We’re anticipating some excellent sessions and conversations exploring the future of clinical trials. We invite you to visit us in booth 20 to find out how our data and analytics support site feasibility, diversity planning, and more. Our own Ryan B. will speak about “Driving Diversity, Equity & Inclusion in Clinical Trials: A Data-Driven Approach.” We hope you’ll join us to learn new strategies for selecting trials sites to improve diversity and health equity. https://hubs.la/Q02YJ6FM0 See you soon! #crosummit #crosummit2024 #healthequity #clinicaltrialdiversity #healthcaretechnology #clinicaloutsourcinggroup

Getting acclimated to a new technology platform in order to get the most out of it can take time. H1 accelerates that process by providing customized trainings that support the individual needs of each user. See how Katie Shin works closely with H1 to identify the tools and capabilities that best support her team at Sumitomo Pharma America, Inc. This individualized approach helps her MSL team to optimize their account planning. See how: https://lnkd.in/e295SWZC You can learn more about HCP Universe here: https://hubs.la/Q02YmNPh0 #sumitomo #smpa #medicalaffairs #MSLs #HCPengagement #healthIT #healthcaretechnology #healthcareinnovation

Merck and AstraZeneca have announced a successful Phase 3 study of their MEK inhibitor Koselugo, which showed a statistically significant and clinically meaningful improvement in certain adult patients with neurofibromatosis type 1 (NF1) compared to placebo. NF1 leads to overactive enzymes, which cause cells to grow into typically noncancerous tumors around the nerves. Koselugo blocks those enzymes to slow down tumor growth. While the FDA approved Koselugo for use in pediatric patients in 2020, 70% of NF1 cases are seen in adults and there is no currently approved therapeutic option for them. Merck and AZ hope to expand their treatment label to include these patients. https://hubs.la/Q02Y3mMN0 #selumetinib #koselugo #neurofibromatosis #nf1 #merck #az #astrazeneca

One important step toward health equity is building trust with patients by improving accessibility. A large component of this is recruiting representative patient populations, which requires better communication tools and strategies. Pamela Fearon explains how she endeavors to grow trust with the patient communities that BioMarin Pharmaceutical Inc. works with in this interview clip. Watch the full conversation here: https://hubs.la/Q02Y6Dfq0 #biomarin #patientdiversity #healthequity #patienttrust #sdoh #patientrecruitment #patientoutreach

In the U.S. alone, millions of patients have been diagnosed with diabetes, with a significant increase in diagnoses being seen over the past decade. It’s notable that, according to our H1 database, diagnoses are growing fastest in the youngest age group followed by 19- to 39-year-olds. Learn more about the insights Trial Landscape can provide in this and other research areas: https://hubs.la/Q02Y6tP20 #diabetesawareness #diabetesawarenessmonth

The Fierce Diversity, Equity & Inclusion Forum free virtual event kicks off next week! If you're registered, we invite you to attend Ryan B.'s presentation and to visit our virtual booth to learn more about how H1 helps life sciences companies build successful diversity planning strategies. https://hubs.la/Q02Y2-jK0 Learn more about our clinical intelligence solutions here: https://hubs.la/Q02Y2Z610 #fierceDEIsummit #diversityandinclusion #healthequity #diversityinhealthcare